Home News Insights Trading halts Paper trading Guide Community My account

Market calendarNext market opening

Display in USD

Loading news article.

U.S. stock guide
Scanner guide
Paper trading guide
Terms of service
Privacy policy
Announcements
FAQ

Support: help@wapeb.comPartnerships: partnership@wapeb.com

WAPE is a free research, analysis and paper trading service. It does not place real securities orders. Market data and AI summaries are for information only, not investment advice or stock recommendations. Information may include delays, errors or estimates. Check original sources and supporting materials. You are responsible for your investment decisions and any resulting gains or losses.

Language한국어 English

Copyright © WAPE. All rights reserved.

Loading news article.

Novartis Halts Experimental ALS Drug Trial but Acquires Brain Delivery Platform | WAPE

Newsbenzinga

Novartis Halts Experimental ALS Drug Trial but Acquires Brain Delivery Platform

Sep 17, 2026, 12:47 ET · Published

Article summary

Novartis halted its mid-stage ALS drug trial for VHB937 but exercised a $125 million option to acquire Sironax's brain delivery platform.

An excerpt from the original article.

Related companies

NVSNVSView stock

Comments —

Comment

Loading comments…